Lixte Biotechnology Company Insiders
| LIXT Stock | USD 3.22 0.13 3.88% |
Lixte Biotechnology employs about 3 people. The company is managed by 11 executives with a total tenure of roughly 50 years, averaging almost 4.0 years of service per executive, having 0.27 employees per reported executive. Breaking down Lixte Biotechnology's management performance can provide insight into the firm performance.
| John Kovach CEO CEO, CFO, Director |
Lixte |
Lixte Biotechnology Management Team Effectiveness
The company has return on total asset (ROA) of (0.6447) % which means that it has lost $0.6447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1107) %, meaning that it created substantial loss on money invested by shareholders. Lixte Biotechnology's management efficiency ratios could be used to measure how well Lixte Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.24 in 2024. Return On Capital Employed is likely to drop to -1.34 in 2024. Change To Liabilities is likely to gain to about 106.3 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 290.7 K in 2024.Common Stock Shares Outstanding is likely to drop to about 1.8 M in 2024. Net Loss is likely to gain to about (5.8 M) in 2024
Lixte Biotechnology Workforce Comparison
Lixte Biotechnology Holdings is rated below average in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 445. Lixte Biotechnology maintains roughly 3.0 in number of employees contributing less than 1% to equities under Health Care industry.
Lixte Biotechnology Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lixte Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lixte Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Lixte Biotechnology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2022-06-01 | 3.5 | 7 | 2 | 700,000 | 0.00 |
| 2018-12-01 | 4.5 | 9 | 2 | 5,150,000 | 1,640,000 |
| 2016-06-01 | 1.0 | 1 | 1 | 200,000 | 0.00 |
Lixte Biotechnology Notable Stakeholders
A Lixte Biotechnology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Lixte Biotechnology often face trade-offs trying to please all of them. Lixte Biotechnology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Lixte Biotechnology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| John Kovach | CEO, CFO, Director | Profile | |
| Bastiaan MSc | CEO President | Profile | |
| Stephen Forman | Director | Profile | |
| Kathleen Mullinix | Independent Director | Profile | |
| Philip Palmedo | Independent Director | Profile | |
| Winson Ho | Director | Profile | |
| Yun Yen | Director | Profile | |
| James MD | Chief Officer | Profile | |
| Robert Weingarten | VP CFO | Profile | |
| Eric JD | VP COO | Profile | |
| John MD | President, Founder | Profile |
About Lixte Biotechnology Management Performance
The success or failure of an entity such as Lixte Biotechnology often depends on how effective the management is. Lixte Biotechnology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Lixte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Lixte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.18) | (1.24) | |
| Return On Capital Employed | (1.27) | (1.34) | |
| Return On Assets | (1.18) | (1.24) | |
| Return On Equity | (1.27) | (1.34) |
The data published in Lixte Biotechnology's official financial statements usually reflect Lixte Biotechnology's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Lixte Biotechnology. For example, before you start analyzing numbers published by Lixte accountants, it's critical to develop an understanding of what Lixte Biotechnology's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Lixte Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lixte Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Lixte Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lixte Biotechnology Holdings. Please utilize our Beneish M Score to check the likelihood of Lixte Biotechnology's management manipulating its earnings.
Lixte Biotechnology Workforce Analysis
Traditionally, organizations such as Lixte Biotechnology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Lixte Biotechnology within its industry.Lixte Biotechnology Manpower Efficiency
Return on Lixte Biotechnology Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.7M | |
| Net Loss Per Executive | 462.5K | |
| Working Capital Per Employee | 1.3M | |
| Working Capital Per Executive | 363.2K |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Lixte Stock analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Return On Assets (0.64) | Return On Equity (1.11) |
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.